Literature DB >> 11159187

Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells.

D Muir1, D Neubauer, I T Lim, A T Yachnis, M R Wallace.   

Abstract

Dermal and plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibromatosis type 1. The goal of the present study was to examine the tumorigenic properties of neurofibromin-deficient human Schwann cells (SCs) that were found to represent a subset of SCs present in approximately half of the total neurofibromas examined. Highly enriched SC cultures were established from 10 dermal and eight plexiform neurofibromas by selective subculture using glial growth factor-2 and laminin. These cultures had low tumorigenic potential in classical in vitro assays yet several unique preneoplastic properties were frequently observed, including delayed senescence, a lack of density-limited growth, and a strong propensity to spontaneously form proliferative cell aggregates rich in extracellular matrix. Western blot analysis failed to detect full-length neurofibromin in any of the neurofibroma SC cultures, indicating that neurofibromin-deficient SCs had a substantial growth advantage. Immunohistochemical staining of the originating tumors showed the majority were comprised principally of neurofibromin-negative SCs, whereas the remainder contained both neurofibromin-negative and neurofibromin-positive SCs. Lastly, engraftment of neurofibromin-deficient SC cultures into the peripheral nerves of scid mice consistently produced persistent neurofibroma-like tumors with diffuse and often extensive intraneural growth. These findings indicate that neurofibromin-deficient SCs are involved in neurofibroma formation and, by selective subculture, provide a resource for the development of an in vivo model to further examine the role of these mutant SCs in neurofibroma histogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159187      PMCID: PMC1850316          DOI: 10.1016/S0002-9440(10)63992-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma.

Authors:  L Kluwe; R Friedrich; V F Mautner
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

2.  Culture of cytogenetically abnormal schwann cells from benign and malignant NF1 tumors.

Authors:  M R Wallace; S A Rasmussen; I T Lim; B A Gray; R T Zori; D Muir
Journal:  Genes Chromosomes Cancer       Date:  2000-02       Impact factor: 5.006

3.  Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis.

Authors:  J Peltonen; S Jaakkola; M Lebwohl; S Renvall; L Risteli; I Virtanen; J Uitto
Journal:  Lab Invest       Date:  1988-12       Impact factor: 5.662

4.  Neurofibromatosis xenografts. Contribution to pathogenesis.

Authors:  O Appenzeller; M Kornfeld; R Atkinson; R D Snyder
Journal:  J Neurol Sci       Date:  1986-06       Impact factor: 3.181

5.  Growth of a rat neuroblastoma cell line in serum-free supplemented medium.

Authors:  J E Bottenstein; G H Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

6.  Oncogene expression in neurofibromatosis.

Authors:  P T Rowley; B Kosciolek; J L Bader
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

7.  Cell culture studies on neurofibromatosis (von Recklinghausen). Characterization of cells growing from neurofibromas.

Authors:  W Krone; R Mao; O S Mühleck; H Kling; T Fink
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

8.  Peripheral nerve sheath tumors: an electron microscopic study of 43 cases.

Authors:  R A Erlandson; J M Woodruff
Journal:  Cancer       Date:  1982-01-15       Impact factor: 6.860

9.  The use of agarose in the determination of anchorage-independent growth.

Authors:  A I Neugut; I B Weinstein
Journal:  In Vitro       Date:  1979-05

10.  Tissue culture studies of neurofibromatosis: effects of axolemmal fragments and cyclic adenosine 3',5'-monophosphate analogues on proliferation of Schwann-like and fibroblast-like neurofibroma cells.

Authors:  G Sobue; K Sonnenfeld; A E Rubenstein; D Pleasure
Journal:  Ann Neurol       Date:  1985-07       Impact factor: 10.422

View more
  27 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells.

Authors:  Philip R Lee; Jonathan E Cohen; Elisabetta A Tendi; Robert Farrer; George H DE Vries; Kevin G Becker; R Douglas Fields
Journal:  Neuron Glia Biol       Date:  2004-05

Review 3.  Spinal reconstruction with pedicle screw-based instrumentation and rhBMP-2 in patients with neurofibromatosis and severe dural ectasia and spinal deformity: report of two cases and a review of the literature.

Authors:  Samuel K Cho; Geoffrey E Stoker; Keith H Bridwell
Journal:  J Bone Joint Surg Am       Date:  2011-08-03       Impact factor: 5.284

4.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

5.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

6.  Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts.

Authors:  Shuqing Liu; Yufeng Tian; Alexandre Chlenski; Qiwei Yang; Peter Zage; Helen R Salwen; Susan E Crawford; Susan L Cohn
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations.

Authors:  Matthew J Smith; Benjamin G Neel; Mitsuhiko Ikura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

8.  Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.

Authors:  Jon P Williams; Jianqiang Wu; Gunnar Johansson; Tilat A Rizvi; Shyra C Miller; Hartmut Geiger; Punam Malik; Wenling Li; Yoh-suke Mukouyama; Jose A Cancelas; Nancy Ratner
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

Review 9.  It takes two to tango: mast cell and Schwann cell interactions in neurofibromas.

Authors:  David H Viskochil
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Immortalization of human normal and NF1 neurofibroma Schwann cells.

Authors:  Hua Li; Lung-Ji Chang; Debbie R Neubauer; David F Muir; Margaret R Wallace
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.